Program

PO3-5-18

The gut hormone INSL5 activates multiple signalling pathways and regulates GLP-1 secretion in NCI-H716 cells

[Speaker] Sheng Yu Ang:1
[Co-author] Bronwyn A Evans:1, Daniel P Poole:1, Romke Bron:1, Jesse J Dicello:1, Ross Ad Bathgate:2, Martina Kocan:2, Dana S Hutchinson:1, Roger J Summers:1
1:Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Australia, 2:The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Australia

Insulin-like peptide 5 (INSL5) is a newly discovered gut hormone with little known about its biological function. Here, we show using RT-qPCR and in situ hybridisation that Insl5 mRNA is highly expressed in the mouse colonic mucosa, colocalised with proglucagon immunoreactivity. In comparison, mRNA for RXFP4 (the cognate receptor for INSL5) is expressed in various mouse tissues, including the intestinal tract. We show that NCI-H716, a human model of the enteroendocrine L-cell, and goblet-like colorectal cells SW1463 and LS513 endogenously express RXFP4. Stimulation of NCI-H716 cells with INSL5 produced phosphorylation of ERK1/2 (Thr202/Tyr204), AKT (Thr308 and Ser473) and S6RP (Ser235/236), and inhibited cAMP production but did not stimulate Ca2+ release. Acute INSL5 treatment had no effect on GLP-1 secretion mediated by carbachol or insulin, but modestly inhibited forskolin-stimulated GLP-1 secretion in NCI-H716 cells. However, chronic INSL5 pre-treatment (18h) increased basal GLP-1 secretion and prevented the inhibitory effect of acute INSL5 administration. LS513 cells were found to be unresponsive to INSL5 despite expressing RXFP4. Another enteroendocrine cell line, mouse GLUTag L-cells did not express detectable levels of Rxfp4 and were unresponsive to INSL5. This study provides novel insights into possible autocrine/paracrine roles of INSL5 in the intestinal tract.

Advanced Search